Metabolic fate of sipoglitazar, a novel oral PPAR agonist with activities for PPAR-γ, -α, and -δ, in rats and monkeys and comparison with humans in vitro

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 2, 2012, Pages 223-231

  Nishihara, Mitsuhiro ^a   Sudo, Miyako ^a   Kamiguchi, Hidenori ^a   Kawaguchi, Naohiro ^a   Maeshiba, Yoshihiro ^a   Kiyota, Yutaka ^a   Takahashi, Junzo ^a   Tagawa, Yoshihiko ^a   Kondo, Takahiro ^a   Asahi, Satoru ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

ADME (absorption; Distribution; Glucuronidation; Metabolism and excretion); Peroxisome proliferator activated receptor (PPAR); Pharmacokinetics; Sipoglitazar

Indexed keywords

3 (3 HYDROXY 1 [4 [(2 PHENYL 1,3 THIAZOL 4 YL)METHOXY]BENZYL] 1H PYRAZOL 4 YL)PROPANOIC ACID; 3 [3 ETHOXY 1 (4 HYDROXYBENZYL) 1H PYRAZOL 4 YL]PROPANOIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SIPOGLITAZAR; SIPOGLITAZAR C 14; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; HAPLORHINI; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RADIOACTIVITY; RAT; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STEADY STATE; STRUCTURE ANALYSIS; THIN LAYER CHROMATOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION;

EID: 84856006231     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-061     Document Type: Article

References (14)

1. Desvergne, B. and Wahli, W.: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 20: 649-688 (1999).
2. Balfour, J. A., McTavish, D. and Heel, R. C.: Fenofibrate.: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs, 40: 260-290 (1990).
3. Després, J. P.: Increasing high-density lipoprotein cholesterol: an update on fenofibrate. Am. J. Cardiol., 88: 30N-36N (2001).
4. Packard, K. A., Backes, J. M., Lenz, T. L., Wurdeman, R. L., Destache, C. and Hilleman, D. E.: Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease. Pharmacotherapy, 22: 1527-1532 (2002).
5. Haffner, S. M., DöAgostino, R., Jr., Mykkanen, L., Tracy, R., Howard, B., Rewers, M., Selby, J., Savage, P. J. and Saad, M. F.: Insulin sensitivity in subjects with T2DM. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care, 22: 562-568 (1999).
6. Balfour, J. A. and Plosker, G. L.: Rosiglitazone. Drugs, 57: 921-930 (1999).
7. Gillies, P. S. and Dunn, C. J.: Pioglitazone. Drugs, 60: 333-343 (2000).
8. Sprecher, D. L.: Lipids, lipoproteins, and peroxisome proliferator activated receptor-delta. Am. J. Cardiol., 100: 20N-24N (2007).
9. Kim, S. N.: Preclinical toxicology and pharmacology of dimethylacetamide with clinical notes. Drug Metab. Rev., 19: 345-368 (1988).
10. Li, A. P., Lu, C., Brent, J. A., Pham, C., Fackett, A., Ruegg, C. E. and Silber, P. M.: Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact., 121: 17-35 (1999).
11. Loretz, L. J., Li, A. P., Flye, M. W. and Wilson, A. G.: Optimization of cryopreservation procedures for rat and human hepatocytes. Xenobiotica, 19: 489-498 (1989).
12. Kintscher, U. and Law, R. E.: PPAREγ-mediated insulin sensitization: the importance of fat versus muscle. Am. J. Physiol. Endocrinol. Metab., 288: E287-E291 (2005).
13. Hyneck, M. L., Munafo, A. and Benet, L. Z.: Effect of pH on acyl migration and hydrolysis of tolmetin glucuronide. Drug Metab. Dispos., 16: 322-324 (1988).
14. Smith, P. C., Hasegawa, J., Langendijk, P. N. and Benet, L. Z.: Stability of acyl glucuronides in blood, plasma, and urine: Studies with zomepirac. Drug Metab. Dispos., 13: 110-112 (1985).